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ABSTRACT Blood–brain barrier (BBB) dysfunction
is a hallmark of neurological conditions such as multi-
ple sclerosis (MS) and stroke. However, the molecular
mechanisms underlying neurovascular dysfunction dur-
ing BBB breakdown remain elusive. MicroRNAs (miRNAs)
have recently emerged as key regulators of pathogenic
responses, although their role in central nervous system
(CNS) microvascular disorders is largely unknown. We
have identified miR-155 as a critical miRNA in neuro-
inflammation at the BBB. miR-155 is expressed at the
neurovascular unit of individuals with MS and of mice
with experimental autoimmune encephalomyelitis
(EAE). In mice, loss of miR-155 reduced CNS extrava-
sation of systemic tracers, both in EAE and in an acute
systemic inflammation model induced by lipopolysac-
charide. In cultured human brain endothelium, miR-155
was strongly and rapidly upregulated by inflammatory
cytokines. miR-155 up-regulation mimicked cytokine-in-
duced alterations in junctional organization and permea-
bility, whereas inhibition of endogenous miR-155 partially
prevented a cytokine-induced increase in permeability.
Furthermore, miR-155 modulated brain endothelial
barrier function by targeting not only cell–cell complex
molecules such as annexin-2 and claudin-1, but also
focal adhesion components such as DOCK-1 and syn-
tenin-1. We propose that brain endothelial miR-155 is a
negative regulator of BBB function that may constitute
a novel therapeutic target for CNS neuroinflammatory
disorders.—Lopez-Ramirez, M. A., Wu, D., Pryce, G.,
Simpson, J. E., Reijerkerk, A., King-Robson, J., Kay,
O, de Vries, H. E., Hirst, M. C., Sharrack, B., Baker
D., Male, D. K., Michael, G. J., Romero, I. A.
MicroRNA-155 negatively affects blood– brain bar-
rier function during neuroinflammation. FASEB J. 28,
000–000 (2014). www.fasebj.org
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In neurodegeneration, stroke, and some neuroin-
flammatory diseases such as multiple sclerosis (MS), the
permeability of the blood–brain barrier (BBB) in-
creases, contributing to the onset and/or worsening of
the disease. Although the mechanisms are not com-
pletely understood, they are thought to involve disas-
sembly of the interendothelial junctional complex
(IJC) and integrin focal adhesion (FA) complexes
(1–3), probably as a result of altered expression of tight
junction (TJ) proteins in response to proinflammatory
cytokines, such as TNF and IFN (4–6). In vitro these
cytokines increase brain endothelial cell (BEC) perme-
ability by modulation of gene expression at transcrip-
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tional and/or post-transcriptional levels (3, 5, 7). Re-
cently, microRNAs (miRNAs) have emerged as important
additional post-transcriptional regulators of gene ex-
pression that can silence target genes by translation
inhibition, mRNA decay, or both (8). Indeed, miRNAs
may constitute an important regulatory control of the
brain endothelial response by fine tuning several of the
cellular and molecular processes triggered by inflam-
matory mediators (7). Furthermore, deregulated
miRNA levels have been demonstrated in several dis-
eases, although their role in the pathogenesis of central
nervous system (CNS) inflammatory disorders remains
to be fully elucidated.
One of the best-characterized miRNAs is miR-155,
which has pleiotropic functions in inflammation, auto-
immunity, and cell plasticity (9–11). Thus far, miR-155
has been shown to induce a decrease in the expression
levels of multiple identified transcripts, but the effect is
modest, characteristic of fine-tuning regulation (12,
13). Moreover, endothelial miR-155 has been shown to
regulate the expression of endothelial nitric oxide
synthase following inflammatory stimulation (14). In
the context of neuroinflammation, miR-155 has been
shown to be one of the most highly elevated miRNAs in
acute MS lesions (15). At a functional level, loss of
miR-155 partially protects mice from the development
of experimental allergic encephalomyelitis (EAE), a
model of MS (10, 16). This finding correlates with its
actions in promoting differentiation of TH17 cells (17),
inhibiting TH2-type immune responses, and mediating
activation of T cells, mononuclear phagocytes, and
dendritic cells (10, 18, 19). However, the symptoms of
EAE are related to increased BBB permeability, and it is
equally possible that miR-155 acts directly in BECs to
modulate BBB function.
In this study, we demonstrated altered levels of
miR-155 at the neurovascular unit in MS brains and
EAE spinal cords. miR-155/ mice showed lower levels
of BBB leakage in EAE and an acute model of systemic
inflammation. Mechanistically, we found that miR-155
regulated human brain endothelial permeability by
targeting molecules involved in cell-to-cell interactions,
annexin-2 (ANXA-2) and claudin-1 (CLDN-1), and
cell-to-extracellular matrix (ECM) interactions, dedica-
tor of cytokinesis 1 (DOCK-1) and syntenin-1 (SDCBP).
Our results demonstrated that brain endothelial miR-
155 negatively regulates BBB function, thereby consti-
tuting a novel therapeutic target for MS and other
neuroinflammatory conditions associated with BBB
breakdown.
MATERIALS AND METHODS
Human and animal tissues
Human brain samples of patients with MS and control
patients without neurological diseases were obtained from
the UK Multiple Sclerosis Tissue Bank (Imperial College
London, London, UK). Adult male and female (10–12 wk)
Biozzi ABH mice were purchased from Harlan UK, Ltd.
(Bicester, UK), and miR-155/ mice and miR-155/ C57BL/6
mice were from Jackson Laboratory (Kent, UK). All proce-
dures were approved after an ethics review, in accordance
with the Animals (Scientific Procedures) Act 1986 of the UK
government and the Animal Research: Reporting of In Vivo
Experiments (ARRIVE) guidelines.
Induction of EAE
EAE was induced in Biozzi ABH mice with 1 mg freeze-dried
mouse spinal cord homogenate in Freund’s adjuvant supple-
mented with 60 mg Mycobacterium tuberculosis H37Ra and
Mycobacterium butyricum. (20) In miR-155/ or miR-155/
C57BL/6 (B6.Cg-miR-155tm1.1Rsky/J) mice, EAE was in-
duced with Hooke Kit (EK-2110) MOG35-55/CFA Emulsion
PTX (Hooke Laboratories, Lawrence, MA, USA), according
to the manufacturer’s protocol. The animals were monitored
daily to assess the development of relapsing–remitting paral-
ysis and scored as follows: 0, normal; 1, limp tail; 2, impaired
righting reflex; 3, hind limb paresis; and 4, complete hind-
limb paralysis. The EAE status was based on paralytic clinical
disease and weight loss/gain as follows: onset of signs (OS):
clinical score 1, with weight loss sampled on d 15 postinduc-
tion; acute-phase paralysis (APP): clinical score 3.5–4, with
weight loss by d 17; recovery: clinical score 3.5–1, with weight
gain by d 20; remission one: clinical score 0.5, with weight
gain by d 28 after induction; chronic: clinical score 3.5, with
stable weight during remission from an episode 3 months
after induction.
Laser capture microdissection (LCM) and isolation
of microvessels
LCM was used to collect enriched brain endothelium RNA,
by a rapid-staining protocol described in Supplemental
Data (21).
Microvessels were isolated from the mouse spinal cords by
a modified method (22). Briefly, EAE or normal ABH mice
were perfused with Hanks’ balanced salt solution containing
0.5% BSA, to rinse out the blood, and the spinal cords were
flushed out. The spinal cords were digested with collagenase
and dispase (1 mg/ml) at 37°C for 1 h, homogenized, and
centrifuged with 25% BSA. The pellet of microvessels under-
went a second digestion for 30 min and was purified by
passage through a 70-m mesh filter.
RNA extraction and microarray analysis
An immortalized human cerebral microvascular endothelial
cell (hCMEC) line, hCMEC/D3, was cultured as described
previously (3). Total RNA from 3 biological replicates were
isolated with the miRNeasy Mini Kit (Qiagen, Crawley, UK),
according to the manufacturer’s protocol. Whole EAE and
control spinal cords or isolated spinal cord microvessels were
homogenized with TRIzol reagent, according to the manu-
facturer’s protocol (Life Technologies, Paisley, UK). Total
RNA of vessels via LCM was extracted with the RNAqueous-
Micro Kit according to the manufacturer’s instructions (Life
Technologies). The quantity (1000 spectrophotometer; Nano-
Drop Technologies, Wilmington, DE, USA) and the quality
(2100 bioanalyzer, RNA 6000 Pico LabChip; Agilent, Palo Alto,
CA, USA) of the total RNA were analyzed. Detailed proce-
dures and complete microarray data are available in the U.S.
National Center for Biotechnology Information (Bethesda,
MD, USA) Gene Expression Omnibus (GEO) under accession
number GSE44694 (http://www.ncbi.nlm.nih.gov/geo).
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Quantitative RT-PCR
The TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems, Warrington, UK) was used to synthesize single-
stranded cDNA according to the manufacturer’s protocol.
Briefly, 2.5 ng of total RNA in the case of LCM material and
10 ng of total RNA in the case of spinal cords, isolated spinal
microvessels, and cultured cells was used to synthesize single-
stranded cDNA. Specific RT and PCR primers for hsa-miR-
155 (000479–4427975), mmu-miR-155 (002571–4427975),
hsa-miR-24 (000402–4427975), or RNU6B (001093–4440887),
the internal control, were obtained from Life Technologies.
TaqMan Universal PCR Master Mix (Life Technologies) was
used to determine the relative levels of hsa-miRs, mmu-miR-
155, and RNU6B. The reaction was then placed in a thermal
cycler (DNA engine Opticon 2; Bio-Rad, Hemel Hempstead,
UK) using an initial step at 95°C for 10 min for activation,
followed by 40 cycles (15 s at 95°C and 60 s at 60°C),
according to the manufacturer’s protocol. The 2CT
method was used for analysis of the data (23). Each control
value for each experiment (unstimulated cells, whole spinal
cords of control mice, microvessels from control human
brains, and mouse spinal cords) was normalized to 1, and
treatment or disease values are expressed relative to control
values. SYBR Green real-time PCR (Qiagen) was used to
determine the relative levels of murine claudin-5, (forward)
CCTTCCTGGACCACAACATC and (reverse) CGCCAGCA-
CAGATTCATACA; Pecam-1, (forward) GGACGATGCGATG-
GTGTATAA and (reverse) GCATCACTGTGCATTTGTACTT;
Gfap, (forward) CAGAGGAGTGGTATCGGTCTAA and (re-
verse) GATAGTCGTTAGCTTCGTGCTT; Cd45, (forward)
CCCTTCTTCTGCCTCAAAGT and (reverse) CACCTGGAT-
GATATGTGGTCTC, whereas actin, (forward) CTCCCTGGAGAA-
GAGCTATGA, and (reverse) CCAAGAAGGAAGGCTGGAAA,
mRNA levels were used as the internal control. The method
2CT was again used for analysis of the data (23). The
results are expressed as relative abundance.
Immunohistochemistry and in situ hybridization (ISH)
EAE mice in acute-phase grade 4 (n5) and control mice
(n5) were perfused with 4% paraformaldehyde (PFA) in 0.1
M phosphate buffer. After cryoprotection in sucrose and
freezing, 15-m sections of the lumbar spinal cords were cut
onto SuperFrost Plus slides (VWR, Lutterworth, UK). The
sections were first treated with 2 g/ml proteinase K (Roche,
Burgess Hill, UK) in 100 mM Tris HCl (pH 7.5) and 50 mM
EDTA at 37°C for 10 min, then fixed again for 5 min in 4%
PFA and dehydrated for 5 min in 70% ethanol. Sections were
prehybridized in hybridization buffer consisting of 50% for-
mamide; 5 saline sodium citrate (SSC; pH 7.0; 20 SSC
contains 3 M NaCl and 0.3 M trisodium citrate; ref. 24); 100
g/ml sheared salmon sperm DNA; and 0.1% Tween-20 at
the miRNA probe hybridization temperature (52°C) for 30
min before the buffer was replaced with hybridization solu-
tion containing probe. Double digoxigenin–labeled miRcury
LNA probe miR-155 oligonucleotide (5 nM; Exiqon, Ved-
baek, Denmark) was hybridized with the sections overnight at
52°C. A similarly labeled LNA scrambled oligonucleotide (5
nM) with no complementary sequence in the mouse was used
as the negative control in the same conditions. After hybrid-
ization, the sections were washed in a series of 5 min SSC
washes at 55°C, consisting of 3 washes with 5 SSC, 3 washes
with 1 SSC, and 3 washes with 0.2 SSC; and incubated for
15 min in a blocking buffer consisting of 0.5% blocking
reagent (Roche) in TBST (100 mM Tris HCl, pH 7.5; 150 mM
NaCl; and 0.1% Tween-20) before incubation overnight in rat
anti-PECAM-1 (1:50; BD Biosciences, Oxford, UK), and sheep
anti-digoxigenin antibody conjugated with alkaline phospha-
tase (1:1000; Roche). Next, the sections were washed with
TBST 4 times, 5 min each, before a wash in alkaline
development buffer (100 mM Tris HCl, pH 9.5; 100 mM
NaCl; 50 mM MgCl2; and 0.1% Tween-20), and then
incubated in NBT/BCIP (1%; Roche) and levamisole
(0.5%; Vector Laboratories, Peterborough, UK) in alkaline
development buffer at 30°C. After they were washed with
TBST 4 times, 10 min each, the sections were incubated for
1 h with secondary goat anti-rat IgG conjugated to Alexa
488 (1:375; Life Technologies). Next, they were washed
with TBST 4 times, 5 min each, before a wash in KTBST (50
mM Tris HCl, pH 7.5; 150 mM NaCl, 20 mM KCl, and 0.5%
Tween-20) to reduce the background signal in the ISH.
The cell nuclei were stained with DAPI Fluoromount-G
(Southern Biotech, Birmingham, AL, USA). The slides
were viewed with a fluorescence microscope and photo-
graphed in color with an Eclipse 80i fluorescence micro-
scope (Nikon, Tokyo, Japan), a CX9000 digital camera
(MBF Bioscience, Williston, VT, USA), and PictureFrame
software (Optronics, Goleta, CA, USA).
Immunocytochemistry
hCMEC/D3 cells were grown to confluence on collagen-
coated Lab-Tek multiwell chamber slides, and immunocyto-
chemistry was performed (3). Briefly, hCMEC/D3 cells were
fixed for 10 min at room temperature with 4% PFA in
phosphate-buffered saline (PBS; pH 7.4) and then permeabil-
ized with 0.5% Triton X-100 in PBS for 5 min. The slides were
blocked with 0.5% BSA for 30 min and incubated with
anti-ZO-1 (1:80; Life Technologies) and anti-vinculin (1:200;
Sigma-Aldrich, Gillingham, UK). For talin immunostaining,
the cells were fixed in methanol for 30 min at 4°C, followed
by cold acetone (maintained at 20°C before use) for 1 min
at room temperature and incubated with anti-talin (1:300;
Sigma-Aldrich) antibody. Cells were washed with PBS and
incubated for 1 h at room temperature with secondary goat
anti-rabbit or -mouse Alexa Fluor 488 (Life Technologies).
The slides were viewed with a BX61 fluorescence microscope
for talin and vinculin (Olympus, Hatfield, UK) or a confocal
microscope (Leica Microsystems, Mannheim, Germany) for
ZO-1, and the images were captured with the CellP or Leica
application suite (LAS) software (Leica Microsystems), re-
spectively. For confocal microscopy, 15 images in Z stacks up
to 2.5 m in depth were acquired with a 100 oil-immersion
objective and projected onto 1 image.
Ectopic expression of miR-155 and siRNA transfections
hCMEC/D3 cells were seeded and grown to 70% confluence
in EGM-2 MV medium before transfection, and the medium
was then changed to EGM-2 MV (Lonza, Slough Wokingham,
UK) supplemented with the following components obtained
from the manufacturer: 0.1% (v/v) rhFGF, 0.1% (v/v) ascor-
bic acid, 0.04% (v/v) hydrocortisone, and 1.25% (v/v) FBS
(hereafter referred to as transfection medium). To ectopi-
cally express miR-155 in hCMEC/D3 cells, we combined 30
nM of pre-miR-155 and the siPORT Amine transfection agent
(Life Technologies) according to the manufacturer’s instruc-
tions. Inhibition of endogenous miR-155 expression was
performed by transfection with 60 nM of hsa-miR-155 miRID-
IAN Hairpin Inhibitor (inhibitor miR-155; ThermoFisher
Scientific, Epsom, UK). To silence human ANXA-2, DOCK-1,
SDCBP, and CLDN-1, we used specific siGENOME SMART-
pools (ThermoFisher Scientific). In both cases, inhibitor-
miRs and siRNAs were combined with Lipofectamine 2000
(Life Technologies), according to the manufacturer’s instruc-
tions. For all oligonucleotide, siPORT (pre-miRs) or lipo-
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fectamine 2000 (inhibitor-miRs or siRNAs) were diluted in
Opti-MEM I (Life Technologies), according to the manufac-
turer’s protocols. The RNA oligonucleotide–lipofection agent
complexes were then dispensed onto the hCMEC/D3 cells
and incubated at 37°C for 6 h (Lipofectamine 2000) or 24 h
(siPORT Amine). The transfection medium with oligonucle-
otide complexes was then replaced with fresh transfection
medium for another 20 h (Lipofectamine 2000) or 2 h
(siPORT Amine). The hCMEC/D3 cells were then main-
tained in EGM-2 MV culture medium without VEGF until the
end of the experiment. Nontargeting, scrambled pre-miR,
inhibitor-miR, or pooled siRNA was used as the transfection
control.
Lentiviral transduction of 3= untranslated region (UTR)
reporter vectors and luciferase assay
The luciferase reporter lentiviral vector constructs containing
the puromycin resistance gene and the Luciferase gene
from the firefly Photinus pyralis with the 3=-UTR of DOCK-1 (acces-
sion number NM_001380), SDCBP (accession number NM_
005625), ANXA-2 (accession number NM_005625), and
CLDN-1 (accession number NM_021101) were obtained from
Applied Biological Materials, Inc. (Vancouver, BC, Canada).
To generate stable hCMEC/D3 cells, we used a multiplicity
of infection of 3 for each of the 3=-UTR lentiviral constructs.
Briefly, hCMEC/D3 cells were seeded to 40% confluence on
24-well plates. The cells were transduced with transduction
medium containing 1  106 transducing U/ml of the lenti-
viral vector and 8 g/ml of polybrene, all suspended in
EGM-2 MV medium. After 12 h of transduction, the transduc-
tion medium was removed, and fresh EGM-2 MV medium was
added. The hCMEC/D3 cells were grown to confluence and
then apportioned into 6-well plates. Next, EGM-2 medium
containing 2 g/ml of puromycin was used to select the
transduced cells.
Detection of luciferase was performed with the Steady-Glo
Luciferase assay system according to the manufacturer’s pro-
tocol (Promega, Madison, WI, USA). Cells were grown on
collagen-coated, white, 96-well cell culture microplates (Greiner
Bio-One, Monroe, NC, USA). Luciferase activity was detected
with a plate reader (BMG, Ortenberg, Germany).
Western blot analysis
Cells were lysed by scraping them into a lysis solution con-
taining 400 l of RIPA buffer (25 mM Tris-HCl, pH 7.6; 150
mM NaCl; 1% Nonidet P-40; 1% sodium deoxycholate; and
0.1% SDS) and a cocktail of inhibitors (5 g/ml aprotinin,
leupeptin, and pepstatin and 1 mM sodium orthovanadate).
After sonication, the amount of protein was determined with
a Bio-Rad DC protein assay. The cell lysates were diluted in
1 Laemmli’s buffer solution, at 95°C for 10 min. Total
protein (25 g/lane) was run on 12 and 10% SDS-polyacryl-
amide gels and transferred onto nitrocellulose membranes
(Amersham, Little Chalfont, UK) by the wet-transfer system
(Bio-Rad). The membranes were blocked with 5% nonfat
milk/0.05% Tween-20 in PBS for 1 h and incubated in the
presence of anti-DOCK-1 (1:200; Cell Signaling, Hitchin,
UK), anti-SDCBP (1:100; AbD Serotec, Oxford, UK), anti-
ANXA-2 (1:3000; BD Biosciences, Oxford, UK), and anti-
CLDN-1 (1:125; Life Technologies) at room temperature
overnight and then with a species-specific secondary anti-
rabbit IgG (1:3000; Life Technologies) or anti-mouse IgG
(1:14000; Pierce Biotechnology, Cheshire, UK) antibody con-
jugated to horseradish peroxidase for 1 h at room tempera-
ture. The immunoblots were then developed by enhanced
chemiluminescence (ECL) detection (Amersham). As a con-
trol for protein loading and transfer, the membranes were
stripped for 40 min at 50°C and incubated with monoclonal
antibody against actin (1:200; Sigma-Aldrich) and revealed as
just described.
In vitro paracellular permeability assays
Cells were seeded onto collagen- and fibronectin-coated
permeable polyester Transwell filter inserts (0.4 m pore, 12
mm diameter; Corning Costar, High Wycombe, UK). The
hCMEC/D3 cells were grown to 85% confluence, transfected
as described earlier, and stimulated for 24 h with TNF and
IFN (1 ng/ml; R&D Systems, Abingdon, UK) or left un-
treated. The culture medium was then removed from the
apical chamber, and 500 l of transport buffer (2% FBS in
DMEM without phenol red) containing 2 mg/ml 70 or 4 kDa
FITC-dextran was added. The paracellular flux of tracer was
then determined (3).
In vivo BBB permeability assays
On d 21 after induction of EAE, BBB permeability was
determined by a published method, with modifications (25).
Briefly, 70-kDa FITC-dextran (250 mg/kg) was injected intra-
venously, and 30 min later, the mice were transcardially
perfused with 0.9% saline (400 ml/kg) and then with 4% PFA
(800 ml/kg). Lumbar enlargement segments (L4–L5) were
cross-sectioned at 20 m thickness and mounted with DAPI-
Fluoromount G. To determine the extravascular intensity of
the FITC-dextran, images were obtained with fluorescence
microscopy at 40 (Zeiss, Cambridge, UK). The images were
quantified with ImageJ software (U.S. National Institutes of
Health, Bethesda, MD, USA) and normalized to fluorescence
values in liver and to tissue area.
For the acute model of systemic inflammation, 12-wk-old
male miR-155/ or miR-155/ C57BL/6 mice were injected
with 2% Evans blue in PBS intraperitoneally at 80 mg/kg. At
18 h, lipopolysaccharide (LPS) from Escherichia coli O111:B4
(4 mg/kg; n6) or PBS alone (n4) was injected intraperi-
toneally (26). After 6 h, blood samples were collected by
cardiac puncture, the mice were perfused with ice-cold 0.9%
saline, and whole spinal cords were flushed out. Each spinal
cord was homogenized in PBS and then mixed with 60%
trichloroacetic acid and incubated on ice for 30 min. Super-
natants were collected by centrifugation at 1000 g for 30 min.
Absorbances of supernatants and plasma were read at 	 620
nm. Each absorbance value was then normalized to weight of
the fresh spinal cords and to plasma concentrations of Evans
blue.
Statistical analysis
Data are expressed as means 
 sem. For all experiments,
the number of independent experiments (n) is indicated.
The statistical analysis for the mRNA microarray was per-
formed by using pairwise comparisons and false discovery
rate. Statistical significance was set at P  0.01, as deter-
mined by LIMMA software (WEHI Bioinformatics, Mel-
bourne, VIC, Australia). For all other experiments, statis-
tical significance was set at P  0.05, as determined by
paired, 2-tailed Student’s t test (cultured cells) or by
analysis of variance (ANOVA) with post hoc comparison and
Tukey HSD correction (animal and human tissue) with
SPSS software (SPSS, Chicago, IL, USA).
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RESULTS
miR-155 is upregulated at the neurovascular unit of
active MS lesions
We first investigated whether proinflammatory miR-155
(9) is altered at the level of the neurovascular unit in
active MS lesions, using the LCM technique to isolate
the microvasculature of white matter. We compared
miR-155 levels in MS lesions with active, ongoing
demyelination and inflammation with MS normal-
appearing white matter (NAWM) and with levels in
the white matter of nonneurological disease controls.
Clinical information and the neuropathologic char-
acterization of MS and control tissues used in this
study are shown in Table 1. We observed that miR-
155 at the neurovascular unit in MS lesions was
significantly increased when compared to levels in
MS-NAWM (Fig. 1) and in control NAWM (data not
shown). These results suggest that increased levels of
miR-155 at the neurovascular unit can be implicated
in BBB dysfunction in MS.
miR-155 is differentially regulated during EAE and
modulates paracellular permeability in vivo
To examine the temporal expression pattern of miR-
155 in vivo, we initially induced EAE in Biozzi ABH
mice, an animal model of MS that shows a predictable
relapsing–remitting paralysis course associated with loss
of BBB integrity at the spinal cord (20). We observed
that the expression levels of miR-155 in whole spinal
cords did not change at the onset of signs (EAE-OS,
animals with limp tail; Fig. 2A). However, we observed
that miR-155 levels were dramatically elevated in ani-
mals with APP (hind-limb paralysis) and during the
recovery phase, reaching levels almost 15 times higher
than in control animals. In addition, miR-155 increased
levels were observed in the remission from the initial
episode and chronic phases after remission from re-
lapses, albeit to a lesser extent. To investigate whether
miR-155 is upregulated in the CNS vasculature during
EAE, we extracted total RNA from isolated spinal cord
microvessels. Quantitative RT-PCR (Fig. 2B) showed
that expression of miR-155 in enriched spinal cord
microvessels of EAE APP mice was 25 times higher than
that of enriched microvessels in control mice. However,
isolated spinal cord microvessels that contain high
levels of markers for endothelial cells (claudin-5 and
Pecam-1) also showed minor amounts of astrocyte
(Gfap) and leukocyte (Cd45) markers (Fig. 2C). To
distinguish the endothelial miR-155 from other CNS
resident cells or leukocytes, we performed ISH in
combination with immunohistochemistry for the endo-
thelial marker PECAM-1 in spinal cords of EAE-APP
mice (Fig. 2D, E). We observed that miR-155 was
upregulated in inflamed blood vessels and partially
colocalized with endothelial PECAM-1 (Fig. 2F–H) and
Glut-1 (Supplemental Fig. S1) expression, but not in
the control littermates (Supplemental Fig. S1).
TABLE 1. Demographic and clinical characteristics of MS and control brain samples
Patient Age/gender Post mortem MS type Disease duration Lesion activity Cause of death
M1 54/F 22 h Secondary progressive Unknown CAL/CL Bronchopneumonia
M2 75/M 22 h Secondary progressive 32 yr CAL/CL Pneumonia
M3 53/M 13 h Secondary progressive 16 yr CAL Pneumonia
M4 34/F 12 h Secondary progressive Unknown AL/CAL/CL Pneumonia
M5 88/F 22 h Primary progressive 30 yr AL/CL Bronchopneumonia
M6 72/F 8 h Relapsing-remitting to
secondary progressive
41 yr AL/CAL/CL Bronchopneumonia
C1 73/M 21 h Control NA NA Cardiogenic shock
C2 64/M 18 h Control NA NA Cardiac failure
C3 82/M 21 h Control NA NA Natural death
C4 35/M 22 h Control NA NA Tongue cancer
C5 84/M 5 h Control NA NA Bladder cancer
C6 82/M 21 h Control NA NA Rheumatoid arthritis
M, MS patient; C, control patient; CAL, chronic active lesions; AL, active lesions; CL, chronic lesions; NA, not applicable.
Figure 1. miR-155 is induced in active lesions of patients with
MS. LCM was used to isolate cerebral blood vessels from
active lesions of patients with MS (MS-AL) and MS-NAWM,
and total RNA was then extracted. miR-155 expression levels
were determined by quantitative RT-PCR. U6B small nuclear
RNA was used as an internal standard. Patient numbers in the
key to the graph refer to those in Table 1.
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These results led us to investigate whether the
resistance of miR-155/ mice to EAE (Fig. 3A and
refs. 10, 16) is in part associated with a decrease in
vascular leakage in the region of inflammation. First,
we observed that the miR-155/ and miR-155/
mice showed similar levels of leakage of 70-kDa
FITC-dextran, indicating that BBB integrity was
maintained in the miR-155/ mice (Fig. 3B, C).
After induction of EAE, the soluble marker was
found to be diffused through the spinal cord paren-
chyma and was in high abundance near the basolat-
eral domain of inflamed blood vessels, indicative of
BBB breakdown in the miR-155/ mice (Fig. 3B, C).
In contrast to the miR-155/ EAE mice, the miR-
Figure 2. miR-155 is induced in spinal cords of EAE mice. A) EAE was induced in Biozzi ABH mice by using spinal cord
homogenates, and total RNA from spinal cords at different clinical stages (OS, APP, recovery, remission, and chronic) were used
to determine levels of miR-155 by quantitative RT-PCR. U6B small nuclear RNA was used as an internal standard. *P  0.05,
**P  0.01, ***P  0.001 vs. littermate controls (n6). B) Total RNA from isolated spinal cord microvessels in EAE-APP mice
and their control littermates were used to determine miR-155 levels by quantitative RT-PCR. Microvessels from the spinal cord
of 3 mice were pooled and analyzed as 1 sample. Data are expressed as means 
 sem. **P  0.01 vs. littermate controls (n3).
C) Total RNA in B was used to determine BEC (Cldn-5 and Pecam-1), astrocyte (Gfap), and leukocyte (Cd45) markers by
quantitative RT-PCR. D) Hematoxylin and eosin staining of a spinal cord from an EAE-APP mouse. Scale bar  500 m.
E) Immune cell infiltration illustrated at higher magnification. Scale bar  50 m. F–H) ISH for miR-155 combined with
immunohistochemistry to identify PECAM-1 cells in the spinal cord of EAE-APP mice with a clinical score of 4. F) Bottom
left: DAPI labels nuclei; white arrows show nucleus of BECs. Top left: expression of miR-155 (black arrow). G) Higher
magnification. Bottom right: immunostaining of the endothelium-specific marker PECAM-1 (white arrows). Top right:
merged image demonstrates colocalization of miR-155 and PECAM-1 (black arrows). H) Higher magnification. Scale
bar  25 m.
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155/ EAE mice showed a 50% reduction in BBB
leakage of the paracellular tracer (Fig. 3B, C). How-
ever, the reduced BBB leakage observed in the
miR-155/ EAE mice may be due not only to a
decrease in neurovascular dysfunction during neuro-
inflammation but also in part to a reduction in
immune cell activation (9, 27).
To investigate the role of miR-155 in inflammation-
induced neurovascular dysfunction with reduced leu-
kocyte infiltration and/or leukocyte-triggered immune
responses, such as TNF secretion (Fig. 3D), we deter-
mined the BBB’s permeability to Evans blue in an acute
inflammation model induced by intraperitoneal injec-
tion of LPS. LPS administration induced a 2-fold in-
crease of Evans blue leakage into spinal cords of the
miR-155/ mice compared to that in the PBS-treated
miR-155/ mice (Fig. 3E). By contrast, no increase in
Evans blue extravasation was observed in the miR-
155/ mouse spinal cords after LPS treatment when
compared with that in the PBS-treated miR-155/ or
miR-155/ mice (Fig. 3E). Overall, these results sug-
gest a potential role of miR-155 expression at the
neurovascular unit in the negative modulation of BBB
function during neuroinflammation.
miR-155 modulates paracellular permeability of brain
endothelium in vitro
We showed evidence of increased levels of miR-155
expressed at the neurovascular unit during neuroin-
flammation (Figs. 1 and 2B, F–H and Supplemental Fig.
S1). However, our in vivo experiments did not unequiv-
ocally exclude indirect effects on neurovascular dys-
function by miR-155 expression in other CNS-resident
cells, including astrocytes and pericytes. To better
understand whether endothelial miR-155 directly me-
diates BBB dysfunction during neuroinflammation, we
next investigated whether proinflammatory cytokines
would alter levels of miR-155 in cultured human BECs.
Indeed, miR-155 was upregulated in the hCMEC/D3
cell line by 2 cytokine treatments, including TNF 
IFN and TNF  IL1, but not by IFN  IL1
treatment (Fig. 4A). We also observed a time- and
dose-dependent increase in miR-155 expression levels
in response to TNF  IFN (Fig. 4B). We next
investigated whether cytokine-induced up-regulation of
miR-155 is associated with increased paracellular per-
meability in BECs. hCMEC/D3 cells were transfected
with pre-miR-155 (Fig. 4C), and paracellular permea-
Figure 3. Inflammation-induced BBB
breakdown is partially prevented in miR-
155/ mice. EAE was induced in miR-
155/ and miR-155/ mice using the
MOG35–55/CFA Emulsion PTX Kit (Hooke
Laboratories). A) Deletion of miR-155
ameliorates EAE. Two-way ANOVA of the
clinical score of all the time points dem-
onstrated a significant difference between
the 2 groups. Data are expressed as means

sem (n10/group). B) At d 21 after in-
duction, mice were injected intravenously
with 70-kDa FITC-dextran (250 mg/kg), and lumbar spinal cords and livers were obtained after perfusion with fixative.
Images of cross sections of spinal cords at the L4–L5 levels were analyzed to determine extravascular fluorescence intensity.
Representative images show control nonimmunized miR-155/ and miR-155/ mice or immunized miR155/ and
miR-155/ EAE mice. Scale bar  25 m. C) Quantification of extravascular intensity of 70-kDa FITC-dextran. For each
mouse, the fluorescence intensity of spinal cord sections was normalized to that of liver sections from the same animal. Error
bars sem (n10). *P 0.05 vs. all other groups; ANOVA with post hoc comparisons and Tukey HSD correction. D) Plasma
levels of TNF in WT and miR-155/ mice 6 h after intraperitoneal injection of LPS (4 mg/kg) assessed by ELISA. Values
are fold change in LPS-treated wild-type (WT) and LPS-treated miR-155/ mice relative to that in PBS-treated WT
(5.03
0.85 pg/ml) and PBS-treated miR-155/ (4.21
0.37 pg/ml) mice, respectively. Error bars  sem (n4 for PBS
group, n6 for LPS group). E) Quantification of efflux of Evans blue in the spinal cords of mice as in D. *P  0.05 vs. all
other groups; ANOVA with post hoc comparisons and Tukey HSD correction. Error bars  sem (n4, PBS group; n6, LPS
group).
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Figure 4. miR-155 contributes to cytokine-induced brain endothelial BBB breakdown in vitro. A) Total RNA was isolated from
hCMEC/D3 cells treated with TNF  IFN, TNF  IL1, or IL1  IFN, to determine miR-155 levels by quantitative
RT-PCR. miR-24 is an example of miRNA that did not change after cytokine treatment. U6B small nuclear RNA was used as an
internal standard. Data are expressed as means 
 sem. **P  0.01 vs. unstimulated cells (n3). B) Confluent monolayers of
hCMEC/D3 cells were stimulated with TNF  IFN at 1, 10, and 100 ng/ml for 24 h or with TNF  IFN (100 ng/ml) at
2, 6, and 24 h, to determine miR-155 levels by quantitative RT-PCR. Control values were normalized to 1; results are expressed
as miRNA levels in TNF  IFN-treated cells relative to those in unstimulated cells. Data are expressed as means 
 sem.
*P  0.05, **P  0.01 vs. unstimulated cells (n3). C) miR-155 expression levels in hCMEC/D3 cells treated with TNFIFN
(1 ng/ml) or transfected with pre-miR-155 (30 nM) for 24 h. miRNA levels are expressed relative to those in control cells or in
cells transfected with scrambled pre-miR. U6B small nuclear RNA was used as an internal standard. Data are expressed as means 

sem (n3). *P  0.05 vs. vehicle-transfected cells; #P  0.05 vs. scrambled pre-miR-transfected cells. D) Brain endothelial
permeability coefficient (Pe) for 70-kDa FITC-dextran was measured in cells transfected with pre-miR-155 or stimulated with
TNF  IFN as in C. Data are expressed as means 
 sem (n3). and *P  0.05 vs. vehicle-transfected cells; #P  0.05 vs.
scrambled pre-miR-transfected cells. E) miR-155 levels were analyzed in hCMEC/D3 cells transfected with scrambled miR
inhibitor (60 nM) or with miR-155 inhibitor (60 nM) in the presence or absence of TNF  IFN (1 ng/ml) for 24 h. U6B RNA
was used as an internal standard. Data are expressed as means
 sem (n3). #P 0.05 vs. scrambled miR inhibitor-transfected cells. F) Pe
for 70-kDa FITC-dextran was measured in hCMEC/D3 cells transfected with scrambled miR inhibitor or miR-155 inhibitor in the presence
and absence of TNF  IFN as in E. Data are expressed as means
 sem (n3). *P 0.05 vs. basal scrambled miR inhibitor-transfected
cells; #P  0.05 vs. cytokine-treated scrambled miR inhibitor-transfected cells.
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bility was assayed. First, we observed that low concen-
trations (1 ng/ml) of TNF  IFN induced a 1.9-fold
increase in the leakage of fluorescent dextrans across
BEC monolayers when compared with that in the
controls (Fig. 4D). Furthermore, the ectopic expres-
sion of miR-155 in hCMEC/D3 cells (Fig. 4C) in-
duced a 1.5-fold increase in the leakage of both 4 (data
not shown) and 70-kDa fluorescent dextrans, when
compared with scrambled pre-miR-transfected cells
(Fig. 4D). In contrast, hCMEC/D3 cells transfected
with miR-155 inhibitor (Fig. 4E) partially reversed (by
40%) the increase in paracellular permeability in the
hCMEC/D3 cells challenged with 1 ng/ml of cytokines
for 24 h (Fig. 4F). These results indicate that miR-155
contributes to the cytokine-induced disruption of the
paracellular seal of the brain endothelium, which re-
sults in increased paracellular permeability to tracers in
vitro.
Overexpression of miR-155 induces changes in the
pattern of gene expression of hCMEC/D3 cells
To identify miR-155 target genes in BECs that might be
implicated in BBB dysfunction relevant to human dis-
ease, we then used mRNA microarray analysis to ana-
lyze changes in mRNA expression of hCMEC/D3 cells
that overexpress miR-155. We observed that 390 tran-
scripts (of 10,600 genes detected) were down-regu-
lated by at least 1.2-fold with a P  0.01 significant
change in overexpression of miR-155 (GEO accession
number GSE44694). Using clueGO (28), we observed
that the 3 most statistically significant biological pro-
cesses identified were translation (P0.01), FAs (P0.05),
and methionine metabolism (P0.05; Fig. 5A). Another
bioinformatic analytical source, DAVID (29), further
identified IJC (P0.05) as a significantly enriched
functional category among the miR-155-down-regu-
lated transcripts in hCMEC/D3 cells.
miR-155 induces reorganization of FAs and TJs in
hCMEC/D3 cells
Since genes involved in FAs were markedly overrepre-
sented in the set of genes down-regulated by the
overexpression of miR-155 in hCMEC/D3 cells, we
used immunocytochemical techniques to investigate
whether FA organization is affected by modulation of
miR-155 levels. Two structural components, vinculin
and talin, showed a characteristic staining pattern of
FAs, manifested by the presence of flat and elongated
structures located centrally and near the cell periphery
in hCMEC/D3 cells transfected with scrambled pre-
miR (Fig. 5B, C). In addition, vinculin immunostaining
was shown to be highly localized at the cell–cell junc-
tions, as shown by the belt-like staining pattern on the
cells’ periphery (Fig. 5B).
After transfection with pre-miR-155, vinculin immu-
nostaining located centrally did not appear to be
affected in the hCMEC/D3 cells (Fig. 5B). However, we
observed a substantial reduction in the staining of
vinculin located at the cell–cell junctions (Fig. 5B).
Ectopic expression of miR-155 also altered talin subcel-
lular distribution located centrally and at cell borders
(Fig. 5C). TNF  IFN-treatment induced a change in
the cell morphology, characterized by elongation of the
cell shape accompanied by a reorganization of vinculin
toward a more centrally localized and punctuate pat-
tern (Fig. 5B). Inhibition of the cytokine-induced in-
crease in miR-155 levels by miR-155 inhibitor partially
rescued vinculin (Fig. 5B), but not talin (Fig. 5C),
delocalization at the cell–cell junctions.
We also observed that ZO-1 showed a continuous
intercellular junction pattern at the cell borders in
hCMEC/D3 cells transfected with scrambled pre-miR
and in nontransfected cells (Fig. 5D). By contrast,
overexpressing miR-155 in BECs induced ZO-1 reorga-
nization, characterized by disruption of its normal
distribution from the cell–cell boundaries, similar to
the effect of cytokines on junctional organization (Fig.
5D). Furthermore, cytokine-induced redistribution of
ZO-1 (Fig. 5D) was partially prevented by miR-155
inhibitor (Fig. 5D). Altogether, these results led us to
investigate the putative target genes involved in the
miR-155-induced changes in FA and IJC organization
that might contribute to alterations in the permeability
of BECs.
Bioinformatic analysis and paracellular permeability
assays identify 4 miR-155 putative targets associated
with barrier dysfunction in hCMEC/D3 cells
Using TargetScan5.0 (8), we identified 63 putative
target genes with a seed match for miR-155 that were
down-regulated by overexpression of miR-155 at the
mRNA level in hCMEC/D3 cells (Fig. 6 and Supple-
mental Table S1). To further select candidate genes
associated with the increased paracellular permeability
induced by miR-155 in BECs, we used additional crite-
ria by including only the genes associated with cell–cell
junctions and/or the integrin adhesome (30–32) and
those that were experimentally validated by 3=-UTR
reporter assays in other cell types (12, 13, 33). Using
this strategy, we identified 7 candidate genes, includ-
ing 4 components of FAs, DOCK-1, SDCBP, palladin
(PALLD), and integrin V (ITGAV), and 3 molecules
in IJCs, ANXA-2, CLDN-1, and prion protein (PRNP)
(Table 2).
We then observed that reducing the expression of
the FA components DOCK-1 and SDCBP induced a
1.4-fold increase in paracellular permeability when
compared with that in the control (Fig. 7A). This effect
was associated with delocalization of both ZO-1 and
vinculin from the cell borders (Fig. 7B). Similarly,
silencing CLDN-1 and ANXA-2 induced a 1.5-fold in-
crease in paracellular permeability when compared
with that in the controls (Fig. 7A). Silencing of CLDN-1
also induced disassembly of ZO-1 from the cell borders
(data not shown). Silencing of the remaining 3 candi-
date genes, PALLD, ITGAV, and PRNP, did not induce
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Figure 5. miR-155 induces changes in the pattern of gene expression of junctional molecules in hCMEC/D3 cells and alters their
subcellular distribution. A) List of genes with down-regulated mRNA transcripts after ectopic expression of miR-155 in
hCMEC/D3 cells, determined by microarray analysis, was used to create a pie visualization map with KEGG, Biocarta, and GO
molecular functions by the ClueGO bioinformatic tool (28). Full data analysis of mRNA transcripts altered by overexpression
of miR-155 in hCMEC/D3 cells can be accessed in GEO (accession number GSE44694). B–D) hCMEC/D3 cells were transfected
with pre-miR-155 or miR-155 inhibitor before addition of TNF  IFN (1 ng/ml) for 24 h. B, C) Vinculin (B) and talin (C)
were used as FA markers and visualized by immunofluorescence. In nontransfected or scrambled pre-miR-transfected
hCMEC/D3 cells, the vinculin and talin staining pattern was located centrally and at the cell borders. Overexpression of miR-155
induced the disappearance of vinculin primarily from the cell borders, whereas talin was delocalized, both from the cell borders
and centrally. TNF  IFN induced reorganization of both vinculin and talin in hCMEC/D3 cells, but only vinculin
delocalization was partially prevented by miR-155 inhibitor. Images are representative of 3 separate experiments. Scale bar 
20 m. D) Arrowheads show ZO-1 immunostaining in hCMEC/D3 cells characteristic of TJs discerned by continuous staining
at the cell borders. Arrows show that miR-155 overexpression or TNF  IFN stimulus for 24 h induced ZO-1 fragmentation
from the cell–cell contacts compared with cells transfected with scrambled pre-miR or treated with vehicle. Knockdown of
miR-155 using miR-155 inhibitor partially prevented cytokine-induced disassembly of ZO-1, as indicated by arrowheads (bottom
right). Images are representative of 4 separate experiments. Scale bar  25 m.
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an increase in the paracellular permeability of the
hCMEC/D3 cells (data not shown).
We next validated the regulatory roles of miR-155 in
FAs and IJCs by using the luciferase reporter assay. The
results showed that miR-155 overexpression in the
hCMEC/D3 cells decreased luciferase activity by 30–
40% in cells carrying the 3=-UTR of DOCK-1, SDCBP,
ANXA-2, or CLDN-1, when compared with the scram-
bled pre-miR controls (Fig. 7C). These results were
further supported by a decrease in the protein levels of
DOCK-1 (65%), SDCBP (50%), ANXA-2 (30%),
and CLDN-1 (50%) in hCMEC/D3 cells overexpress-
ing miR-155, as evidenced by immunoblot analysis (Fig.
7D, E). These results demonstrate that 4 target genes
for miR-155, including 2 components of FAs, DOCK-1
and SDCBP, and 2 components of IJCs, ANXA-2 and
CLDN-1, modulate brain endothelial permeability and
potentially mediate, at least partially, miR-155-induced
BBB breakdown during inflammation.
DISCUSSION
We propose that miR-155 acts as a novel negative
regulator of BBB function during neuroinflammation
by modulating BEC cell-to-cell and cell-to-matrix inter-
actions, thereby contributing to the pathogenesis of
CNS neuroinflammatory disorders such as MS. The
general consensus is that miR-155 is a proinflammatory
miRNA (9) and that it may participate in the harmoni-
zation of cell activation during inflammatory processes
in mammals. Consistent with this proposal, a recent
study has shown that miR-155 is highly expressed in
active inflammatory MS plaques where astrocytes were
identified as one of the potential cellular sources of this
miRNA (15). Our current results further suggest that
miR-155 is highly expressed at the neurovascular unit in
MS active lesions and is differentially upregulated in
mouse whole spinal cords at different stages of EAE.
Indeed, we used an animal model that shows a repro-
ducible and predictable relapsing–remitting EAE (20).
During EAE-OS there is an infiltration of leukocytes
and BBB leakage (20) without any significant changes
in miR-155 levels in whole spinal cords, suggesting that
the cellular source of miR-155 at this stage is low
and/or difficult to detect if the increase in miR-155 is
restricted to a few affected areas of the neurovascular
unit. However, miR-155 levels are rapidly upregulated
during paralysis in the initial APP at a time when
maximum cell infiltration is occurring around the
vasculature (20). Furthermore, in this EAE model, the
recovery occurs when the animals begin to gain weight
and clinical scores subside (20). This is accompanied by
a gradual recovery of BBB function and reduction of
cellular infiltration of the CNS (20), but we did not
observe a decrease in the proinflammatory miR-155
levels. This result suggests that the proinflammatory
cytokine profile at this stage is still high. It is tempting
to speculate that activation mechanisms that initiate the
Figure 6. miR-155 predicted targets in hCMEC/D3 cells.
hCMEC/D3 cells were transfected with pre-miR-155 or with
scrambled pre-miR as the control. RNA was extracted and
analyzed using microarray profiling. hCMEC/D3 cells expressed
10,600 genes of the 24,000 genes tested. Shown are 2-way
Venn diagram of genes down-regulated by ectopic expression of
miR-155 and putative predicted targets for miR-155 expressed by
hCMEC/D3 cells. Sixty-three genes were identified to have
target sites for miR-155 and were down-regulated after ectopic
expression of miR-155 in hCMEC/D3 cells. Table 2 shows the 7
candidate genes involved in miR-155-induced barrier break-
down in hCMEC/D3 cells.
TABLE 2. Candidate genes involved in miR-155-induced BBB breakdown in hCMEC/D3 cells
TargetScan
HeLa cells
B cells; Xu et al. (33) DR Gene symbol Gene name FA JCGuo et al. (11) Selbach et al. (11)
   CLDN-1 Claudin 1 
   ANXA-2 Annexin A2 
   PRNP Prion protein (p27–30) 
     SDCBP Syntenin 1 
   DOCK-1 Dedicator of cytokenesis 1 
   PALLD Palladin 
   ITGAV Integrin V 
Criteria for selection: 1) genes down-regulated at the mRNA level by ectopic expression of miR-155 (the full data analysis of mRNA
transcripts altered by overexpression of miR-155 in hCMEC/D3 cells can be accessed in GEO with accession number GSE44694); 2) genes with
function related to cell–cell or cell–matrix adhesion; and 3) miR-155 predicted targets as identified by databases (Targetscan) and/or
experimentally validated by 3= UTR-reporter assays in other cell types (see refs. 12, 13, 33). DR, down-regulated in hCMEC/D3 cells; FA, focal
adhesion; JC, junctional complex.
11BRAIN ENDOTHELIAL MIR-155 IN NEUROINFLAMMATION
resolution of the inflammatory response during the
recovery phase also, by an unknown molecular mecha-
nism, desensitize the neurovascular unit to the effects
of miR-155 before any decrease in miR-155 levels is
observed. This desensitizing effect may also occur in
the first remission phase when inflammatory lesions
resolve and BBB dysfunction is minimal but miR-155
levels are still elevated (20). Another cellular source of
miR-155 in EAE spinal cords may be activated leuko-
cytes, since mononuclear cells, including T lympho-
cytes with increased miR-155 levels, infiltrate the CNS
parenchyma in EAE (10, 16). However, increased miR-
155 levels at the neurovascular unit were observed in
isolated microvessels of EAE spinal cords. We also
observed by ISH that, during neuroinflammation, miR-
155 appeared to be expressed in the microvasculature
as well as in large blood vessels, including venules.
Previous studies have shown that BBB breakdown is a
fundamental event during the course of MS and that
the magnitude of the neurovascular dysfunction in EAE
is associated with the neurological severity of the dis-
ease (34). Furthermore, mice deficient in the bic/miR-
155 gene showed partial resistance to the development
of EAE in this and previous studies (10, 16) and, in this
study, we showed that loss of miR-155 plays a protective
role against BBB leakage in the region of inflammation.
In addition, using LPS as an acute model of systemic
inflammation with reduced leukocyte infiltration and
circulating TNF response, we observed that loss of
miR-155 attenuates the increase in BBB permeability.
However, these in vivo experiments are not conducive
to unequivocally excluding the effect of miR-155 on
other CNS-resident cells, astrocytes and pericytes, dur-
ing neurovascular inflammation. To test the hypothesis
that brain endothelial miR-155 is involved in BBB
dysfunction, we examined the effects of miR-155 on
brain endothelial barrier functions in cell culture.
Brain endothelial miR-155 was upregulated by proin-
flammatory cytokines in a time- and dose-dependent
manner, an effect that coincides with cytokine-medi-
Figure 7. miR-155 silences genes associated with cell–cell and cell–matrix junctions, leading to increased paracellular
permeability in hCMEC/D3 cells. A) Silencing of DOCK-1, SDCBP, ANXA-2, or CLDN-1 using specific siRNAs induced an increase
in hCMEC/D3 cell paracellular permeability to FITC-dextran. Error bars  sem (n3–4). *P  0.05, **P  0.01 vs. nontarget
siRNA negative control. B) Silencing of DOCK-1 or SDCBP using specific siRNAs induced delocalization of ZO-1 and vinculin
from the cell periphery, denoted by arrows. Images are representative of 3 separate experiments. Scale bar  20 m. C) Cells
were transiently transfected with pre-miR-155 or scrambled pre-miR in hCMEC/D3 cells stably expressing luciferase constructs
with the 3=-UTR of the indicated genes. Ectopic expression of miR-155 reduces luciferase activity for each construct. Data are
expressed as means
 sem (n3). *P 0.05 vs. scrambled pre-miR-transfected cells. D) DOCK-1, SDCBP, ANXA-2, and CLDN-1
protein levels were determined by Western blot analysis in hCMEC/D3 cells transfected with scrambled pre-miR or pre-miR-155.
The same blots were reprobed with anti-actin antibody as indicated for each gene. E) Protein expression levels in D were
quantified using ImageJ software and presented as the means 
 sem (n3). *P  0.05 vs. scrambled pre-miR-transfected
cells.
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ated brain endothelial barrier permeability (3). More-
over, in our study, the ectopic expression of miR-155
mimicked the cytokine-induced increase in permeabil-
ity, whereas knockdown of endogenous miR-155 par-
tially prevented cytokine-induced barrier disruption in
BECs, indicating an active role for endothelial miR-155
in inflammation-induced BBB breakdown. Hence,
brain endothelial miR-155 appears to be a proinflam-
matory miRNA, but it is induced by inflammation
and/or infection at early times after stimuli, suggesting
that it contributes to the early stages of inflammation at
the neurovascular unit.
The mechanism by which miR-155 may exacerbate
the breakdown of the BBB appears to involve 2 differ-
ent cellular pathways. First, miR-155 may be an impor-
tant “control node” for the expression of IJC molecules
in brain endothelium, thereby directly affecting the
organization of cell–cell junctions. Consistent with our
results, Kong et al. (35) reported that miR-155 induced
delocalization of ZO-1 from the cell–cell contacts in
tumorigenic epithelial cells. In this study, we found that
miR-155 may modulate BEC permeability and TJ orga-
nization by directly targeting the components of IJCs:
CLDN-1 and ANXA-2. CLDN-1, a target for miR-155,
has an important barrier function, at least in epithelial
cells (36), although its expression by BECs in vivo is
controversial (37). Recently, it has been shown that
ectopic expression of CLDN-1 in C57BL/6 mice pre-
vents BBB leakiness in EAE animals, compared with
that in littermate controls (32). Furthermore, loss of
CLDN-1 at the BBB has also been associated with
barrier dysfunction in glioblastoma multiforme (38)
and hepatitis C infection (39). In addition, ANXA-2,
another miR-155 target, has been shown to regulate
endothelial cell morphology and junctional integrity
via its association with VE-cadherin (31). However, little
is known about the contribution of ANXA-2 to strength-
ening the BEC barrier. In our study, silencing of
ANXA-2 expression had significant consequences for
BEC barrier function in vitro. Hence, miR-155 direct
targeting of at least 2 components of CNS IJCs may lead
to increased BBB permeability.
A second cellular pathway modulated by endothelial
miR-155 involves FA organization, which may also lead
to increased BBB permeability after application of a
cytokine stimulus. We observed that miR-155 affects the
distribution of vinculin and talin in BECs, suggesting
alterations in the cellular attachment to their matrix
substrate. Vinculin is a cytoskeleton-associated protein
that plays an important role in FA assembly and
strength (40). Talin, another FA molecule, directly
interacts with the cytoplasmic tail of -integrins, induc-
ing their activation (41). Indeed, 1-integrin-mediated
adhesion of BECs to the surrounding ECM has recently
been shown to be critical for stabilizing claudin-5 in TJs
and for BBB integrity (42). In our study, we observed
that miR-155 has the capacity to directly target FA
components in BECs and that down-regulation of at
least some of these components may lead to increased
BEC permeability. For instance, DOCK-1 forms part of
focal contacts and participates in the downstream in-
tegrin signal transduction pathway by forming com-
plexes with the engulfment and cell motility (ELMO)
protein (43). It is possible that the DOCK-1-ELMO
complex, a guanine nucleotide exchange factor, regu-
lates endothelial permeability by modulating the activ-
ity of Rho-family GTPases such as Rac-1, although this
does not exclude the possibility that FA disassembly
directly leads to increased BEC permeability (44).
Indeed, another FA molecule that we found to be
regulated by miR-155 in cultured BEC is SDCBP, an
adaptor and scaffold protein that contains PDZ (post-
synaptic density protein-95, postsynaptic discs large,
and zona occludens-1) motifs. Initially, SDCBP was
shown to interact with syndecans, which are heparan
sulfate proteoglycans that assist cell adhesion and pro-
mote attraction and concentration of growth factors at
the cell surface (45). It has also been shown that
knockdown of SDCBP prevents fibronectin-induced
formation of integrin-1/FAK/c-Src complex, which
may play an important role in the downstream focal
contact signaling pathway (46). Therefore, it appears
that not only structural FA proteins are important for
stabilizing TJs and the brain endothelial barrier but
also FA adaptor and signaling proteins. Whereas in
other cell types such as fibroblasts (47), miR-155 may
promote migration by silencing genes implicated in
modulating cell-to-matrix attachment, endothelial miR-
155 may indirectly contribute to increased BBB perme-
ability via targeting FA components.
In summary, we propose that miR-155 modulates key
features of the brain endothelial barrier during inflam-
mation and may play an important role during the
pathogenesis of CNS inflammatory disorders that affect
the BBB. In addition, endothelial miR-155 may act as
an effector of inflammatory mediators associated
with promotion of inflammation and subsequent
barrier breakdown. In this study, we demonstrated
the possibility that miR-155 contributes to BBB break-
down during neuroinflammation by altering the phe-
notype and function of neurovascular endothelium,
in particular components of cell-to-cell and cell-to-
matrix adhesion pathways, thereby revealing poten-
tial therapeutic targets for the amelioration of CNS
inflammatory disorders.
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